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Abstract
Objective: Transparent evidence-based decision making has been promoted
worldwide to engender trust in science and policy making. Yet, little attention has
been given to transparency implementation. The degree of transparency (focused
on how uncertain evidence was handled) during the development of folate and
vitamin D Dietary Reference Values was explored in three a priori deﬁned areas:
(i) value request; (ii) evidence evaluation; and (iii) ﬁnal values.
Design: Qualitative case studies (semi-structured interviews and desk research).
A common protocol was used for data collection, interview thematic analysis and
reporting. Results were coordinated via cross-case synthesis.
Setting: Australia and New Zealand, Netherlands, Nordic countries, Poland, Spain
and UK.
Subjects: Twenty-one interviews were conducted in six case studies.
Results: Transparency of process was not universally observed across countries or
areas of the recommendation setting process. Transparency practices were most
commonly seen surrounding the request to develop reference values (e.g. access
to risk manager/assessor problem formulation discussions) and evidence
evaluation (e.g. disclosure of risk assessor data sourcing/evaluation protocols).
Fewer transparency practices were observed to assist with handling uncertainty in
the evidence base during the development of quantitative reference values.
Conclusions: Implementation of transparency policies may be limited by a lack of
dedicated resources and best practice procedures, particularly to assist with the
latter stages of reference value development. Challenges remain regarding the best
practice for transparently communicating the inﬂuence of uncertain evidence on
the ﬁnal reference values. Resolving this issue may assist the evolution of nutrition
risk assessment and better inform the recommendation setting process.
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Historic public health scares (e.g. in the UK following the
Phillips inquiry into variant CJD/new variant CJD, the
human prion disease caused by the BSE crisis in 1996)
contributed to a general commitment for transparency,
openness and evidence-based (information indicating
whether a belief or proposition is true or valid) decision
making in food-related science and policy(1). This resulted
in the formal separation of science and policy activities
and adoption of the risk analysis framework(2).
The risk analysis framework was ﬁrst adapted for use
in the food area following a joint FAO/WHO expert
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consultation in 1995(3). The framework has been comprised
of three interconnected activities: (i) risk assessment
(scientiﬁc evaluation of health effects); (ii) risk manage-
ment (policy decisions to minimise risk); and (iii) risk
communication (exchange of risk information in/outside
the framework). A principle has been to maintain the
separation of activities while recognising the interaction
between activities (e.g. separation can vary from different
organisations to different groups/tasks within the same
organisation responsible for different activities)(3).
Central to implementation of the risk analysis frame-
work has been the encouragement of transparency and
disclosure of uncertainty in the evidence underlying
scientiﬁc advice (risk assessment) or political decision
making (risk management)(2,4). The transparent handling
of uncertainty may refer to ‘explicit recognition of any
uncertainty either in the current state of knowledge or in
the adequacy of the available data’ (e.g. accuracy/quality
or degree of incomplete/quantity of data)(5). Transparency
and openness have been promoted to achieve greater
accountability and credibility during risk analysis, improved
communication between stakeholders (e.g. science, policy,
industry, health practice) and safeguard the abuse of public
organisation power or resources(2,6–8).
Policies of transparency can be found across various
public health disciplines responsible for risk analysis
activities, such as the European Food Safety Authority
(EFSA), the National Institute for Health and Care Excellence
(NICE) and FAO/WHO(2,4,9). Implementation of these
policies requires the process and outcome of a risk ana-
lysis activity to be evident and obvious, i.e. documented
and understandable (transparent), as well as accessible
(open)(7,8,10,11). This may be related to the organisation
responsible for a risk analysis activity (e.g. disclosure of
organisation role and responsibility, membership, con-
ﬁdentiality signed agreements, declaration of interest) or
the technical content of the activity (e.g. disclosure of non-
published requests, methods, ﬁndings and conclusions via
websites, reports and manuscripts, meeting minutes and
agendas, open consultations and open meetings, release
of data and study results, etc.).
A commitment to transparency and openness may
seem the correct thing to do in view of due diligence
towards scientiﬁc practice(8). Nevertheless, the imple-
mentation of transparency per se may be limited
or represent certain challenges(11). Detailing and providing
access to all elements of the risk analysis process may be
challenging in terms of resource, technical, conﬁdentiality
or wider trust issues (e.g. articulating the nature of risk
assessment or inherent uncertainty of scientiﬁc endeavour;
detailing contradictory views during commonplace expert
discussions while maintaining unanimity in the ﬁnal scientiﬁc
advice)(12,13).
Nutrition risk assessment to derive micronutrient
Dietary Reference Values (DRV) is an area where greater
transparency and openness has been encouraged(14). DRV
are developed in the ﬁrst two steps of the risk assessment
process. The identiﬁcation of a nutrient-related hazard
in a food/food group is established in step one (nutrient-
related hazard identiﬁcation). The qualitative/quantitative
evaluation of adverse health effects associated with a
nutrient is established in step two (nutrient-related hazard
characterisation). This constitutes the development of
DRV. In a full risk assessment, DRV (steps one and two)
would be combined with a nutrient intake/exposure
assessment (step three) to assess exposure in relation to
the DRV (step four)(15). Once completed, the scientiﬁc
advice from the risk assessment is used to inform develop-
ment of recommendations in risk management. Thus,
the development of DRV can be considered a precursor to
the development of micronutrient recommendations.
Recommendations are deﬁned as population targets of
micronutrient intake necessary for adequate growth,
function and health throughout the human lifespan. These
are widely used in monitoring and evaluating population
intakes as well as in developing public health policies,
interventions and dietary risk communications (e.g. food-
based dietary guidelines to help the population meet
recommended intakes)(14,16).
The widespread use of DRV (directly or indirectly via
recommendations) belies the complexity and uncertainty
with which they are developed. The ﬁrst stage of DRV
development has been referred to as the ‘nutrition
problem formulation stage’. During problem formulation
risk managers and assessors are required to establish a
shared understanding of the problem and the purpose of
the risk assessment(10). Previously, the primary focus of
DRV development was to devise intakes related to nutrient
deﬁciency or overconsumption. More recently the remit of
DRV has expanded to also encompass intakes for health
beneﬁts (including intakes to delay the onset of disease).
Yet, the evidence base surrounding the role of nutrition
on health has been far from certain. Hence, prevailing
scientiﬁc knowledge is used to handle limitations and
uncertainty in the evidence (unknown, unreliable or
indeﬁnite evidence), develop plausible assumptions and
complete the DRV development process(14,17).
Guidelines have been produced to assist with the
development of DRV (e.g. the Institute of Medicine’s
Dietary Reference Intakes (DRI) for the USA and Canada;
the EFSA Panel on Dietetic Products, Nutrition and Allergies’
Scientiﬁc Opinion on principles for deriving and applying
DRV)(16,18). Yet, no standardised approach or agreed
best practice has been used to set DRV. Furthermore,
disparity has been observed in DRV developed by different
national or international bodies (e.g. vitamin D DRV).
The lack of agreed best practice and disparity in DRV has
led to confusion among inter/national policy decision
makers, health professionals, the food industry and
consumers(19).
An open and transparent DRV process has the potential
to assist with understanding why values differ between
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countries by clearly detailing what, why and how deci-
sions were made, particularly regarding the degree of
uncertainty in the evidence and how this was handled
or inﬂuenced the strength of the ﬁnal risk assessment
conclusions/resultant reference values(19,20). This would
inform the debate on DRV development best practice.
Furthermore, increased documentation, understanding
and accessibility to the DRV process could contribute to
the responsible use of DRV throughout risk management
and risk communication activities(2,14).
The European Commission-supported Network of
Excellence EURRECA (EURopean micronutrient RECom-
mendations Aligned, FOOD-CT-20006-36196, 2007–2012)
was tasked with reviewing the methodologies used to
derive DRV, assessing the reasons for value disparity and
the potential for methodological alignment across national
and international DRV development. Early EURRECA
ﬁndings highlighted the importance of the nutrition pro-
blem formulation stage to ensure risk assessment activities
remained achievable while also fulﬁlling the requirements
of risk managers(20). Further research suggested DRV
disparity was unlikely to be explained by differences in
concepts, deﬁnitions or deﬁned population groups.
Instead it was considered likely to be due to different
interpretations or assumptions taken while accounting for
uncertainty and limitations during evidence evaluation(19).
Finally, research identiﬁed variation in the transparency of
different types of bodies in relation to how risk managers
integrated DRV with other types of advice to develop
recommendations(20). The current study built upon these
previous ﬁndings. Transparency and openness during the
DRV risk assessment process was explored, with a parti-
cular focus on how uncertainty in the evidence base was
handled. Three areas of interest, likely to demonstrate
handling of uncertainty in the evidence base, were iden-
tiﬁed during DRV development: (i) the request to develop
DRV; (ii) the process of DRV evidence evaluation; and
(iii) the integration of evidence to develop ﬁnal DRV.
Method
Design
Qualitative in-depth case studies explored the handling
of uncertain evidence and the transparency of vitamin D
and folate DRV development in six countries/regions:
(i) Australia and New Zealand (ANZ); (ii) the Netherlands
(NL); (iii) the Nordic countries (Denmark, Finland, Iceland,
Norway and Sweden; NOC); (iv) Poland (PL); (v) Spain
(ES)(21); and (vi) the United Kingdom (England, Northern
Ireland, Scotland and Wales; UK).
Each country/region produced a descriptive report
based upon semi-structured interviews with at least two
advisory committee members together with desk research
(Table 1). A common protocol was followed throughout.
The interview schedule, desk research and ﬁnal case study
report all centred upon the transparency and handling of
uncertain evidence in three predeﬁned areas: (i) the
request to develop DRV, e.g. source of request, scope of
request, reasons for the request; (ii) the process of DRV
evidence evaluation, e.g. selection and evaluation of
evidence; and (iii) integration of evidence to develop ﬁnal
DRV, e.g. formation of quantitative numbers and advisory
committee report.
Transparency and openness was qualitatively judged via
the availability of accessible, understandable documenta-
tion on the DRV process (e.g. downloadable/upon request
meeting agendas, minutes and key discussion documents;
ability to attend open meetings and consultations and
documentation surrounding DRV; documented risk analysis
policy, organisation role and responsibility, membership,
declaration of interest; stakeholder involvement; etc.).
Vitamin D and folate were selected due to their
prioritisation as micronutrients of interest in Europe(22).
Countries/regions were originally selected from Europe
with a subsequent opportunity taken to also collect data
in Australia and New Zealand. The countries/regions
sampled represented diversity in the age and method of
Table 1 Country/region, number of interview samples, response rate, and references and associated updates for the folate and
vitamin D DRV
Country No.
% response
rate Folate Vitamin D
ANZ 4 57 NHMRC 2006(38) NHMRC 2006(38)
NL 4 67 HCN 2003(27), HCN update 2008(39) HCN 2000(40), HCN update 2008(41)
NOC 4 80 NNR 2004(42) NNR 2004(42), *NNR 2012 published subsequent
to data collection(26)
PL 4 100 Jarosz and Bułhak-Jachymczyk 2008(43) Jarosz & Bułhak-Jachymczyk 2008(43)
ES 3 100 Moreiras 2011(44), Ortega 2011(45), Serra Majem
2001 (SENC)(46), Martínez 2010 (FESNAD)(47)
Moreiras 2011(44), Ortega 2011(45), Martínez 2010
(FESNAD)(47)
UK 2 33 COMA 1991(48), SACN folate 2006(49) COMA 1991(48), SACN vitamin D update 2007(50);
*new vitamin D DRV expected 2014
DRV, Dietary Reference Values; ANZ, Australia and New Zealand; NL, Netherlands; NOC, Nordic countries (Denmark, Finland, Iceland, Norway and Sweden);
PL, Poland; ES, Spain; UK, United Kingdom; NHMRC, Australian National Health and Medical Research Council; HCN, Health Council of the Netherlands
(Gezondheldsraad); NNR, Nordic Council of Ministers’ Nordic Nutrition Recommendations; SENC, Spanish Society of Community Nutrition; FESNAD,
Federación Española de Sociedades de Nutrición, Alimentación y Dietética; COMA, Committee on Medical Aspects of Food Policy; SACN, Scientific Advisory
Committee on Nutrition.
*Recommendations under development at time of study data collection.
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developing DRV as well as in geographical location, socio-
cultural factors and institutional infrastructure. Data sets
were collected from December 2010 to June 2011.
Interviews
Interviewees were recruited due to their involvement in
the advisory committee and/or development of vitamin D
or folate reference values. This included members of the
advisory committee and/or members of relevant advisory
committee working subgroups. The response rate ranged
from 33 % (UK) to 100 % (ES and PL; Table 1). Consent
was obtained from each participant, with interviews
recorded and later transcribed verbatim. All data were
made anonymous and held in accordance with the local
data privacy laws (e.g. UK Data Protection Act)(23). The
semi-structured interview schedule was piloted and
devised by the research team with questions focused upon
the transparency and handling of uncertainty in the
aforementioned three areas of DRV development.
Desk research
Sourced documents related to the development of vitamin
D or folate DRV in each country/region. Keyword searches
were conducted of advisory committee websites, publica-
tion websites (e.g. PubMed Central) and search engines
(e.g. Google). Documents referred to during the interviews
and manual searches of references elicited several addi-
tional documents. Further information was obtained in the
UK case study via observation at two open advisory
committee meetings (14 February 2011 and 7 June 2011).
Desk research key search terms included variants of the
nutrient name (e.g. folate and folic acid), variants of the
word DRV (e.g. micronutrient recommendations, nutrient
intake values, nutritional objectives) and/or the advisory
committee name (e.g. Health Council for the Netherlands).
Excluded documents were not relevant to vitamin D or
folate DRV, the speciﬁc country/region, human nutrition
or healthy populations or were duplications from previous
searches. Desk research was led and organised by ques-
tioning the transparency and handling of uncertainty in the
aforementioned three areas of DRV development.
Analysis
Initial interview and desk research analysis was conducted
in the native language using template analysis and a
skeleton coding structure created and modiﬁed by partners
during preliminary analyses(24). Case studies consisted of
an English-translated summary of interview- and/or desk
research-identiﬁed themes with illustrative quotes orga-
nised by the three areas (value request, evidence evalua-
tion and ﬁnal values). Construct validity was upheld by
limiting the subjective collection of data and performing
traceable literature searches. Internal validity was upheld
by encouraging several interpretations of the data to be
considered. Multiple sources of information (triangulation
between interview, desk research and DRV reports where
possible) were used to cross-reference (corroborate/
dispute ﬁndings). The uniform framework of case study
reporting allowed further analysis where cross-case
synthesis was used to describe and identify any differ-
ences or similarities across countries/regions in the trans-
parency and handling of uncertainty(25). One research
team member conducted the cross-case synthesis. The
qualitative software NVivo version 9 (2010) was used to
organise case study data. A subsection of the data was
cross-coded by another research team member. One
fewer theme was identiﬁed by the second coder. This was
subsequently dropped from further analysis. Agreement
on remaining themes and sub-themes was 91%. Inter-
pretation of cross-case analysis results was reﬂected back
to case study authors and amended where necessary.
Data presentation
Interview quotes have been displayed in the tables using
double quotation marks and italics. Verbatim quotes have
been modiﬁed in publication for improved readability.
Case study/desk research text has been displayed in the
tables using single quotation marks. The term ‘micro-
nutrient recommendation’ was used in the interview
schedule and throughout the present study. This term
could be translated and understood across the cases
sampled as pertaining to either micronutrient DRV or the
use of values to make recommendations.
Note that quotes have been unaltered in this respect and
differences in the terminology can be seen as cases refer to
their respective micronutrient recommendations, e.g. ‘The
term “Nordic Nutrition Recommendations” refers to a set
of dietary reference values (DRVs) for essential nutrients
that includes the average requirement (AR), recommended
intake (RI), upper intake level (UL), lower intake level (LI),
and reference values for energy’(26).
Results
Transparency and openness of the DRV process (i.e.
documentation, understanding and accessibility) varied
across the countries/regions (cases) and different areas of
the DRV development process studied. Results have been
presented below in the three areas studied: (i) the request to
develop DRV; (ii) the process of DRV evidence evaluation;
and (iii) the integration of evidence to develop ﬁnal DRV.
Request to develop DRV
In ES, where multiple sets of DRV were developed by
different individuals, teams and organisations (Spanish
Society of Community Nutrition (SENC), Federación
Española de Sociedades de Nutrición, Alimentación y
Dietética (FESNAD), Universidad Complutense de Madrid),
minimal documentation could be found to clarify details on
the source, scope or reason for the request to develop DRV
(meeting agendas/minutes, discussion documents, press
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releases, website pages, ﬁnal report details, journal
publications). However, the Spanish interview data were
more informative and interviewees openly discussed
details surrounding the request for previous DRV. In
contrast, greater information (via desk research and
interview data) on the request to develop DRV was
available in countries/regions with an ofﬁcial set of DRV
and a clear body tasked with their development, such as in
ANZ (National Health and Medical Research Council
(NHMRC)/Ministry of Health (MOH)), NL (Health Council
of the Netherlands (HCN)), NOC (Nordic Council of
Ministers (NCM)), PL (National Food and Nutrition Institute
(Instytutu Żywności i Żywienia; IŻŻ)) and UK (Committee
on Medical Aspects of Food Policy (COMA)/Scientiﬁc
Advisory Committee on Nutrition (SACN); Tables 1 and 2).
Regarding the source of the request to develop DRV,
Spanish interviewees cited the majority of activity was
undertaken by independent and academic institutions. On
the other hand, in the ﬁve cases of ANZ, NL, NOC, PL and
UK the requests were predominantly sourced from the
government or within the advisory committee as a set
programme of work.
Across all six cases the reasons provided for the request to
develop DRV ranged from acknowledged discrepancy
between local DRV and those of other countries, DRV age,
the emergence of new data, a set time cycle for the
programme of work, information provision to assist policy
option selection and triggers from monitoring practices, such
as clinical health outcomes or markers of chronic disease
risk (e.g. neural tube defects, LDL). However, details on the
ﬁnal trigger to initiate a request for particular nutrient DRV to
be reviewed or developed were not always transparent, i.e.
the inﬂuence of lobbying (professional, academic, com-
mercial or special interest group) on initiating or suppressing
any development of DRV. Similarly, the criteria for judging
when DRV were ‘too old’, when there was ‘sufﬁcient’ new
evidence to initiate renewing DRV or at what point disease
incidence constituted a public health issue to address were
not always transparently documented.
The scope of request differed between cases. In the
ANZ, PL and ES cases the scope of the request centred
upon the utilisation and adaptation of international DRV to
each respective country/region (predominantly the US/
Canadian DRV in ANZ and PL; various international DRV
in ES). This was clearly detailed in ANZ. The NHMRC was
asked to assess the body of evidence used to establish the
US/Canadian DRV (and any relevant literature that had
subsequently been released) and provide an opinion on
one of four courses of action: whether they should adopt,
adopt with minor changes, adopt with substantial changes
or reject the US/Canadian DRV in ANZ.
The remaining three cases (NL, NOC and UK) all
referred to the importance of clarifying the scope of the
request and iterative interactions between government
representatives and advisory committee members during
the nutrition problem formulation (e.g. to demarcate risk
assessment/risk management activities or develop values
for deﬁciency/adequacy/optimal/toxicity). Problem for-
mulation was deemed necessary to ensure the request
would be both appropriate and achievable (e.g. scientiﬁc
limits of knowledge and resource constraints such as
expertise, ﬁnance, time). Transparency appeared to be
the greatest regarding the current UK vitamin D DRV
development process. Here, the public was allowed to
attend an open meeting where the scope of the request
was discussed (also known as ‘terms of reference’ in the
UK) and online access was made available for downloading
detailed meeting minutes and discussion documents
surrounding request clariﬁcation.
Process of DRV evidence evaluation
Several discussions were undertaken on how to evaluate
and interpret evidence that contained methodological and
theoretical uncertainties (e.g. folate assay method, folate
Table 2 Request to develop DRV
Value request Quotes: case study text or interview [case study/participant reference]
Source of request “No, it has not been the Government as in other countries... there have been private initiatives but nothing coming
from the Government.” [ES]
“…items of work can come to the SACN in three ways: they can come from Government, requests from Government;
from the Committee itself; and from… anybody just writing to the Committee. The reality is the Committee’s
workload means it’s mainly driven by Government.” [UK]
Reason for request “All nutrients are reviewed one way or the other every eight year and then they put special focus on some of them
every time. And vitamin D has been discussed very much in the last years, also in America, so that is why vitamin D
is one of the chosen nutrients.” [NOC]
“Concerning the folate, firstly quite huge discrepancies between Polish recommendations and those in other
countries. Secondly, elevated blood homocysteine level and quite big percentage of neural tube defects in Polish
population. Also the health policy, how to improve the situation (…).” [PL]
Scope of request “What we did is making the question more precise and operationalised it, like it is called, in cooperation with the
MHWS. Let’s say, the original questioning is a bit adapted in such a way that we could better provide answers.” [NL]
‘The Chair emphasised the need for a broad risk assessment, which would inform government whether the newly
available data on vitamin D has implications for UK public health policy.’ [UK]
DRV, Dietary Reference Values; ES, Spain; SACN, Scientific Advisory Committee on Nutrition; UK, United Kingdom; PL, Poland; MHWS, Ministry of Health,
Welfare and Sport; NL, Netherlands.
“Italics and double quotation marks denote interview quotes”; ‘single quotation marks denote case study/desk research text’.
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equivalents, uncertainty factors, bioavailability factors,
vulnerable population groups, mechanisms of action,
multiple nutrient interactions). These discussions were
present in the cases which adopted/adapted existing
international DRV as well as those which developed their
own DRV (Table 3). For example, the ANZ, PL and ES
cases made reference to the evidence evaluation pre-
viously conducted in the original DRV as well as the
additional evidence evaluation required to ensure adapted
DRV were up-to-date and relevant to their respective
country/region.
To increase the transparency and scientiﬁc rigour of the
evidence evaluation process, four cases (ANZ, NL, NOC,
UK; Table 4) used protocols to guide evidence evaluation,
address uncertainty in the data and limit interpretation
bias. These evidence evaluation protocols differed slightly.
Yet, all four cases provided guidance on the systematic
reviewing of literature (including meta-analyses), the
assessment of individual study quality/risk of bias and
accounting for uncertainty when weighting or deciding the
strength of the evidence base.
ANZ, NL and NOC used a series of checklists to assess
study quality and a number of categories to differentiate
between results from different study designs. The UK also
utilised a series of checklists but discouraged the use of
numerical grading. It was clearly acknowledged that a
degree of subjective judgement was still required with the
application of these protocols, especially when moving
from the quality assessment of each study to collating the
strength of the total evidence. Nevertheless, the following
of a protocol for evidence evaluation and reporting
of results was seen by these four cases as important
steps towards a standardised approach to the evidence
evaluation decision-making process.
Integration of evidence to develop ﬁnal DRV
Interviewees across all cases acknowledged that evidence
evaluation did not constitute the end of the DRV develop-
ment process. Evidence evaluation ﬁndings needed to be
appraised in the context of the original request to form the
ﬁnal DRV. Expert judgement was required to take account
of the underlying certainty of the evidence, decide the
strength of evidence and conclude with speciﬁc reference
values. This stage of the process appeared to be less stan-
dardised with few transparent protocols available to aid the
expert deliberation and consensus seeking decision-making
process (Table 5).
The four cases which employed evidence evaluation
protocols (ANZ, NL, NOC, UK) appended these protocols
to reports and used them to guide descriptions of the
strength and degree of certainty in the evidence under-
lying each DRV. In addition, prior to the publication
of DRV reports, the standard practices of peer review
(NL, NOC, PL) and invited or open consultation (ANZ,
NL, NOC, PL, UK) provided an element of transparency
and credibility to the process. Nevertheless, from the
interviews it was clear that considerable discussions
occurred between the evidence evaluation stage and
the creation of the ﬁnal DRV, even in relation to the
wording or terminology used to describe DRV concepts
(particularly PL) or the strength of evidence/degree of
uncertainty (particularly UK). However, the details from
many of these discussions were rarely communicated in
the ﬁnal report.
Two interviewees (ES, NL) speciﬁcally mentioned that
the exact discussions undertaken by those developing
DRV were not commonly reported. Reasons cited for this
included a concern for the conﬁdentiality of those who
developed the recommendations as well as a belief that it
Table 3 Process of DRV evidence evaluation
Evidence evaluation Quotes: case study text or interview [case study/participant reference]
Protocols for evidence
evaluation
‘The NHMRC explains the reviewers were directed to take the body of evidence and key papers used to
establish the USA/Canadian dietary reference intakes and provide an analysis of any vital missing documents
and/or documents which were published after the Canadian dietary reference intakes were established, using
the NHMRC’s six levels of evidence.’ [ANZ]
“Historically we have had recommended intakes in Spain, as well as food composition tables, but it was not clear
how they were made (...).” [ES]
‘In the 2006 reconsiderations the committee applied a rating system for weighing quality of scientific evidence
based on CBO’s “evidence based guideline development” and SIGN grading system, in which the highest
level of evidence include only systematic reviews of good quality [2 & 6, appendix C & D resp.]. Despite, there
were various uncertainties related to scientific evidence.’ [NL]
‘Systematic literature reviews will be performed to minimise potential reporting bias through comprehensive and
reproducible searches using clearly defined search strategies together with clearly defined and described
selections and reporting protocols. This means that the reviewing of literature will be more systematic in
connection with NNR5 than it has been in earlier rounds.’ [NOC]
‘The consultation document [Code of Practice for Scientific Advisory Committees, published by the Government
Office for Science 17th Sep 2010] was circulated to members, along with a short paper “How SACN operates”
to describe SACN practices relevant to the specific areas covered by the consultation questions. This was
appended with a copy of the Committee’s framework for evaluation of evidence.’ [UK]
DRV, Dietary Reference Values; NHMRC, Australian National Health and Medical Research Council; ANZ, Australia and New Zealand; ES, Spain; CBO, Dutch
Institute for Healthcare Improvement; SIGN, Scottish Intercollegiate Guidelines Network; NL, Netherlands; NNR5, Nordic Council of Ministers’ Nordic Nutrition
Recommendations, 5th edition; NOC, Nordic countries (Denmark, Finland, Iceland, Norway and Sweden); SACN, Scientific Advisory Committee on Nutrition;
UK, United Kingdom.
“Italics and double quotation marks denote interview quotes”; ‘single quotation marks denote case study/desk research text’.
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Table 4 Protocols used to assess study quality/risk of bias across cases (PL/ES unknown)
ANZ (NHMRC 2000)(51) NL (CBO 2007(52) and SIGN 50 2007(53)) NOC (NNR5 Working Group 2011)(54) UK (SACN 2008)(55)
Assessment of study
quality/risk of bias
Quality checklist Quality checklist Quality checklist (total quality score) Quality checklist
Six evidence categories; Six evidence categories; Three evidence categories;
I: RCT systematic review A1: Systematic reviews (2 grade A2
studies + )
A: Low level of bias. Considered valid.
High quality. Valid estimation of nutrient
exposure. Control for confounders in
design and analyses.
II: ≥1 RCT
A2: Randomised, double-blind
comparative intervention study (good
quality/size) B: Bias not sufficient to invalidate results.
Do not meet all A category criteria.
May be missing information, thus
difficult to assess limitations
III-1: Pseudo-RCT
B1: Systematic reviews of good quality
(2 grade B2 studies + )
C: Significant bias that may invalidate the
results
III-2: Comparative studies with concurrent
controls, cohort, case–control or
interrupted time series
B2: Comparative (not A2), good quality
cohort or patient case studies
III-3: Comparative studies with historical
control, ≥ 2 single arm/interrupted time
series without parallel control group
C: Non-comparative studiesIV: Case series, post/pre test
D: Opinion of the committee
Strength of evidence
summary
Narrative summary Four categories; Four categories; Narrative summary
Convincing: 1 grade A1 or ≥2 grade A1 Convincing (high): Causal/absence of
relationshipProbable: 1 grade B1 or ≥2 grade B2
Probable (moderate): Causal relationshipInsufficient: 1 grade A2 or B2 or grade C
Limited–suggestive (low): Suggestive of
effect direction
Insufficient: Based upon the committee’s
opinion (grade D)
Limited–no conclusion (insufficient):
Limited quantity, inconsistent effect
direction
PL, Poland; ES, Spain; ANZ, Australia and New Zealand; NHMRC, Australian National Health and Medical Research Council; NL, Netherlands; CBO, Dutch Institute for Healthcare Improvement; SIGN, Scottish
Intercollegiate Guidelines Network; NOC, Nordic countries (Denmark, Finland, Iceland, Norway and Sweden); NNR5, Nordic Council of Ministers’ Nordic Nutrition Recommendations, 5th edition; UK, United Kingdom;
SACN, Scientific Advisory Committee on Nutrition; RCT, randomised controlled trial.
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was unnecessary to report every aspect of discussions that
occurred during the deliberations before a consensus
was reached. An exception was observed in NL when a
disagreement of an advisory committee member could not
be resolved during the formation of the folate DRV(27).
Consequently, a footnote was added to the Dutch report
detailing a minority position of disagreement regarding the
expression of folate v. folic acid as well as folate equiva-
lent selection.
Discussion
Transparency and openness of the DRV process was not
universally adopted across countries or areas of the DRV
development process studied. Implementation of transpar-
ency policies may be limited by a lack of dedicated
resources and best practice procedures, particularly to assist
with the latter stages of reference value development.
Findings aligned with previous research regarding
transparency in risk management activities(20). The countries
with dedicated advisory committees for risk assessment
activities (ANZ, NL, NOC, PL and UK) demonstrated
greater transparency of the DRV process than ES, where
coordinated action at a national level was in its infancy
and DRV had been developed by dedicated individuals.
Arguably, NL, NOC and UK appeared to display the
most transparency (also potentially ANZ, although the
underpinning US/Canadian DRV setting process was not
studied). Similarly to the above, this could be explained
by a greater legal and clariﬁed role of the relevant advisory
committees and their responsibilities (demarcation between
risk assessors, risk managers and risk communicators),
a higher political priority or greater dedication of resources
for nutrition and a longer tradition of DRV development.
Furthermore, both NOC and UK were currently updating
DRV at the time of study. Thus, the nature of transparency
observed may have reﬂected the current increased calls for
transparency and been associated with the most recent
micronutrient DRV setting processes.
All cases demonstrated differences in transparency (in
general and speciﬁc to the handling of uncertain evidence)
across the three a priori areas studied (value request,
evidence evaluation and ﬁnal values). Based upon these
ﬁndings, the status quo for current best practice regarding
transparent and open handling of uncertainty in nutrition
risk assessment has been discussed below.
Regarding the request to develop DRV, transparency
was increased via documentation and accessibility to the
iterative discussions between risk assessors, risk managers
and others in problem formulation. These discussions
acknowledged the uncertainty and limitations of the
evidence base available to ensure the feasibility of the risk
assessment task. This transparent detailing of the source,
scope and reasons for any DRV request corresponded
with guidance seen in a number of international risk
assessment procedural documents (e.g. the nutrition pro-
blem formation stage before nutrition risk assessment
activity in CODEX Alimentarius; deﬁning the problem
in the EURRECA framework for setting micronutrient
recommendations)(10,14).
Transparency in risk assessment evidence evaluation is
designed to minimise the probability of bias(28). Best prac-
tice for transparent handling of uncertainty in the cases
studied referred to the documented protocols designed to
guide and standardise the process of sourcing and inter-
preting evidence. Bias was reduced by employing an
independent body to conduct the review and reproduci-
bility was increased by employing standardised systematic
literature review processes. Difﬁculties were still seen
regarding the handling of uncertainty during evidence
evaluation and communicating how this inﬂuenced the
quantiﬁcation/qualiﬁcation of risk (e.g. the merits of
grading different types of evidence). In addition, whether
Table 5 Integration of evidence to develop final DRV
Final values Quotes: case study text or interview [case study/participant reference]
Reporting of strength and
uncertainty in evidence
‘Published throughout the 2006 NRV document are justifications which state how each nutritional
recommendation was established. The NHMRC states that a decision should be made about what
is feasible and appropriate in a given situation and the extent to which reasonable standards have
been met by the available body of evidence’. [ANZ]
‘Although the NRV are evidence-based wherever possible, the data to establish recommendations is
generally very limited (…) Therefore, the Working Party had to rely on subjective professional
judgements to estimate recommendations from alternative age, gender or life stage categories.’
[ANZ]
‘NNR 2004 where there is a chapter for each micronutrient where recommendation are stated followed
by discussion of the evidence and uncertainty.’ [NOC]
“Well, maybe not all uncertainties are published. In other words, it is clear that there have been
discussions, comments, questions that have not been published (…).” [ES]
“(…) the exact discussion that takes place and the names of the committee members who said what,
this is confidential.” [NL]
DRV, Dietary Reference Values; NRV, Nutrient Reference Values; NHMRC, Australian National Health and Medical Research Council; ANZ, Australia and New
Zealand; NNR, Nordic Council of Ministers’ Nordic Nutrition Recommendations; NOC, Nordic countries (Denmark, Finland, Iceland, Norway and Sweden);
ES, Spain; NL, Netherlands.
“Italics and double quotation marks denote interview quotes”; ‘single quotation marks denote case study/desk research text’.
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restricting a review to evidence from randomised
controlled trials or meta-analyses limited the scope of the
review or the utility of the ﬁnal advice/reference values.
However, the constant updating and disclosure of
evidence evaluation procedures in the most recent cases
reﬂected an ability to detail the overall strength of
evidence reviewed.
Few protocols were available to assist with the articula-
tion of, or guide the transition from, evidence evaluation to
the integration of evidence and development of quantitative
values/ﬁnal DRV. This has been highlighted previously in
the health-care area, where difﬁculties have been observed
translating evidence evaluation into scientiﬁc advice for use
in recommendation/guideline development(29,30). These
ﬁndings support the requirement for further initiatives such
as the EFSA consultation exercise in 2013 on how to con-
duct consistent procedures for expert elicitation during risk
assessment(31).
Cases demonstrated that consensus seeking was an
essential stage of the DRV development process, designed
to increase validity and reliability of decisions rather than
relying upon an individual’s judgement. However, it was
difﬁcult to identify the best practice for transparently
developing quantitative DRV; values that require a certainty
not always apparent in the underlying data. The production
of a transparent DRV report documenting the complexity
of evidence-based expert decision making, the strength of
advice and the areas of uncertainty remained a challenge.
This had the potential to pose subsequent problems for
the interpretation of DRV by those outside the advisory
committee (e.g. responsible for setting micronutrient
recommendations/relevant toxicology risk assessment
activities)(32–34).
The present study was based upon qualitative case
studies. Therefore, the selection of micronutrients, coun-
tries and the three a priori deﬁned areas of study may
have limited external validity and the degree to which
these ﬁndings can be transferred outside the sample
studied. The authors recognise the study would have
beneﬁted from including analysis of other countries that
develop micronutrient DRV, e.g. the USA/Canada. The
exploratory nature of the present study justiﬁed the use of
a qualitative design and steps were taken to limit biased
interpretation. A common protocol and the three a priori
deﬁned areas of study were employed to maximise study
rigour via clarity of the research goal and the consistent
method of data collection, analysis and reporting. This
also enabled the combination of data across countries.
Construct validity was upheld by limiting the subjective
collection of data, regular monthly research team meetings
and performing traceable literature searches. Internal
validity was upheld by encouraging several interpretations
of the data to be considered. To maintain the cultural
context and authenticity of the data, the majority of
qualitative interpretation was conducted in the native
language and information from interviews, observation or
desk research provided the ability to cross-reference
ﬁndings. The case studies (data collection, analysis and
reporting) were led by the three a priori deﬁned areas and
did not represent the totality of the DRV development
process. Nevertheless, they have provided an insight into
the nature of transparency, in particular regarding the
handling of uncertain data, available in an evidence-based
decision-making process across multiple countries/regions.
Debate shall continue regarding the best practice for
nutrition risk assessment, particularly handling uncertainty
in the evidence surrounding nutrition, diet, lifestyle and
health and rating the overall evidence underpinning
DRV(35). Future discussions may focus on adaptations to the
risk analysis framework to facilitate increasing requirements
for nutrition risk–beneﬁt assessment in the development
of DRV(26,36). Furthermore, how to meet the challenge of
incorporating developing evidence bases into risk assess-
ment, such as those related to individual differences (e.g.
metabolomics), non-randomised controlled trial study
designs or whole-diet approaches (e.g. epidemiology)(15).
It may not be possible or necessary for all countries/
regions to follow an aligned DRV risk assessment proce-
dure nor for all reference values to be identical. However,
transparency, as well as increasing the accountability and
credibility of DRV development, can facilitate the sharing
of best practice to inform the evolution of nutrition risk
assessment. Therefore, the recent transparency initiatives
from the EFSA, such as proposals to promote public access
to risk assessment technical data, are to be welcomed(37).
Conclusion
Implementation of transparency policies may be limited
by a lack of dedicated resources and best practice pro-
cedures, particularly to assist with the latter stages of
reference value development. Challenges remain regard-
ing the best practice for transparently communicating the
inﬂuence of uncertain evidence on the ﬁnal reference
values. Resolving this issue may assist the evolution of
nutrition risk assessment and better inform the recom-
mendation setting process.
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